CAMBRIDGE, Mass.– Rectify Pharmaceuticals, Inc., (“Rectify”) a biotechnology company developing small molecule disease-modifying therapeutics that restore and enhance ABC transporter function, today announced the appointment of Sachiyo Minegishi as Chief Operating Officer.
“We are delighted to welcome Sachiyo to Rectify’s management team and look forward to drawing on her diverse leadership experiences leading biotech companies as we advance our novel programs through the clinic and into commercialization,” said Rajesh Devraj, Ph.D., President and Chief Executive Officer of Rectify. “Sachiyo is an accomplished leader skilled in navigating companies through important clinical, financial, and corporate milestones, and her expertise will be instrumental in advancing our pipeline focused on restoring ABC transporter function for patients with serious genetic and large common ABC transporter mediated diseases.”
Ms. Minegishi brings 20 plus years’ experience in the biotechnology industry. She most recently served as Chief Financial Officer at Akouos, Inc., where she helped lead the acquisition of the company by Eli Lilly. Previously, Ms. Minegishi was Vice President, Global Program Lead at bluebird bio and in charge of leading cross-functional teams through global development for a portfolio of gene therapies for Sickle Cell Disease. Earlier, Ms. Minegishi held leadership roles at Aegerion Pharmaceuticals, Human Genome Sciences, Genzyme, and Amgen. She began her career in investment banking at Merrill Lynch, with a focus on execution of equity financing and mergers and acquisitions in the biotechnology industry. Ms. Minegishi earned a B.S. in Chemical Engineering and Economics from the Massachusetts Institute of Technology and an M.B.A. from the Wharton School of the University of Pennsylvania.
“Rectify is the first to characterize and address the broad opportunity of the ABC transporter proteome,” said Ms. Minegishi. “I am excited to work with the team and the individuals and families affected by ABC transporter mediated diseases to advance Rectify’s first development candidates into the clinic.” (IANS)
